| Bioactivity | CHNQD-01255 is an orally active Arf-GEFs inhibitor with potent anti-hepatocellular carcinoma (HCC) efficacy[1]. |
| Invitro | CHNQD-01255 (0-1 μM approximately, 72 h) inhibits HepG2 and BEL-7402 cell proliferation[1]. Cell Proliferation AssayCHNQD-01255 (0-1 μM approximately, 72 h) inhibits HepG2 and BEL-7402 cell proliferation[1]. Cell Line: |
| In Vivo | CHNQD-01255 (5- 45 mg/kg, p.o.) inhibits tumor growth in HepG2 tumor-bearing xenograft mice[1].CHNQD-01255 exhibits a high safety profile with MTD values exceeding 750 and 100 mg/kg for p.o. and i.p. administrations in mice[1]. Animal Model: |
| Name | CHNQD-01255 |
| CAS | 2756173-91-6 |
| Formula | C23H29NO6 |
| Molar Mass | 415.48 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yao-Yao Jiang, et al. Design and Characterization of a Natural Arf-GEFs Inhibitor Prodrug CHNQD-01255 with Potent Anti-Hepatocellular Carcinoma Efficacy In Vivo. J Med Chem. 2022 Sep 22;65(18):11970-11984. |